EHA 2026 | Advances and ongoing challenges in chronic myeloid leukemia management
Jorge Cortes, MD, The University of Alabama at Birmingham, Birmingham, AL, discusses the major advances and ongoing challenges in chronic myeloid leukemia (CML). Dr Cortes reviews the long-term impact of tyrosine kinase inhibitors (TKIs), the emergence of newer therapies, and the remaining unmet needs related to treatment-free remission, tolerability, and quality of life (QoL) for patients with CML. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think it’s become a very interesting time in CML. It’s been 30 years since Brian Druker published the in vitro data on imatinib, 25 years since we have imatinib approved. And after a lot of progress there and then with second generation, it looked like we were done. And little by little, we started realizing there’s many more challenges. And now we have a series of new drugs, bosutinib recently, and many others that are being developed that look very exciting...
I think it’s become a very interesting time in CML. It’s been 30 years since Brian Druker published the in vitro data on imatinib, 25 years since we have imatinib approved. And after a lot of progress there and then with second generation, it looked like we were done. And little by little, we started realizing there’s many more challenges. And now we have a series of new drugs, bosutinib recently, and many others that are being developed that look very exciting. And that is because we still have a lot of issues that we need to overcome. Only a fraction of patients can stop therapy effectively. The patients who continue therapy, they have a lot of these low-grade toxicities, quality of life, tolerability issues. We still have questions about, for example, the subset of patients that have ASXL1 mutations. So there’s a lot of questions that we’re still trying to answer. It’s good that we have a resurgence of research trying to address these questions, and we’re going to be talking about some of those questions and upcoming possible solutions for that.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
